Loading...
Market
How much additional funding will Brenus Pharma secure for Phase II clinical trials by March 31, 2025?
3
Resolution / Starting Odds
Less than €10M • 25%
Between €10M and €20M • 25%
Between €20M and €30M • 25%
More than €30M • 25%
Official announcement from Brenus Pharma or financial news outlets
Story
Brenus Pharma Secures €22.2M ($25M) to Accelerate Cancer Vaccine Trials
Sep 18, 2024, 07:37 AM
Brenus Pharma, a Lyon-based biotech company specializing in the development of precision cancer vaccines, has successfully raised €22.2 million ($25 million) in a Series A funding round. The financing was led by Angelor and will be used to accelerate clinical trials of its cancer vaccines. This significant investment underscores the growing interest and support for innovative cancer treatment solutions in the biotech sector.
View original story
Similar markets
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Less than £50 million • 25%
£50 million to £100 million • 25%
£100 million to £150 million • 25%
More than £150 million • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Less than $50M • 25%
$50M - $100M • 25%
$100M - $150M • 25%
More than $150M • 25%
No additional funding • 25%
Up to $10 million • 25%
$10 million to $50 million • 25%
Over $50 million • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%